Re-Evaluating the Transplant Glomerulopathy Lesion—Beyond Donor-Specific Antibodies
Chutani A, Guevara-Pineda D, Lerner G, Menon M. Re-Evaluating the Transplant Glomerulopathy Lesion—Beyond Donor-Specific Antibodies. Transplant International 2024, 37: 13365. DOI: 10.3389/ti.2024.13365.Peer-Reviewed Original ResearchTransplant glomerulopathyLonger-term graft survivalCell-mediated immune mechanismsChronic allograft damageNon-HLA antibodiesDonor-specific antibodiesAnti-HLA alloantibodiesChronic allograft dysfunctionPathogenesis of transplant glomerulopathyPost-transplant yearComplement-mediated injuryShort-term outcomesAllograft dysfunctionAllograft damageGraft lossGraft survivalRenal transplantationEtiological diagnosisPodocyte stressHistological manifestationsImmune mechanismsMorphological lesionsGlomerulopathyTransplantationReview articleAdvancing mouse models for transplantation research
Cravedi P, Riella L, Ford M, Valujskikh A, Menon M, Kirk A, Alegre M, Alessandrini A, Feng S, Kehn P, Najafian N, Hancock W, Heeger P, Maltzman J, Mannon R, Nadig S, Odim J, Turnquist H, Shaw J, West L, Luo X, Chong A, Bromberg J, group A. Advancing mouse models for transplantation research. American Journal Of Transplantation 2024, 24: 1362-1368. PMID: 38219866, PMCID: PMC11239793, DOI: 10.1016/j.ajt.2024.01.006.Peer-Reviewed Original ResearchMouse modelMechanisms of transplant rejectionTranslation to clinical trialsFood and Drug Administration-approved drugsMouse transplantation modelEffective clinical therapiesAdvanced mouse modelsTranslation of experimental findingsClinical outcomesTransplantation modelTransplant rejectionClinical trialsMouse studiesClinical therapyTransplantationClinical researchPhysician-scientistsGenetic variabilityTherapyStatistical power analysis